Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Nanotechnology is a common term for nanoscale science, engineering and technology, which offers extraordinary economic and technological benefits. Healthcare is one of the most prominent field of research in nanotechnology. Nanomedicine can be understood as a field of diagnosing, treating and preventing disease using molecular tools and knowledge of the human body.

Statistics:

The global nanomedicine market is estimated to account for US$ 454.8 Bn in terms of value by the end of 2027.

Global Nanomedicine Market: Drivers

High prevalence of chronic diseases is expected to propel growth of the global nanomedicine market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, opening of a NanoTherm treatment centers is also expected to aid in growth of the market. For instance, in March 2020, MagForce AG and the Hufeland Klinikum GmbH announced the conclusion of a joint cooperation agreement and the planned opening of a NanoTherm treatment center for brain tumors at the Mühlhausen site in Thuringia, Germany.

Statistics:

North America held dominant position in the global nanomedicines market in 2019, accounting for 35.4% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1: Global Nanomedicine Market Share (%) Value, By Region, 2019

Nanomedicines  | Coherent Market Insights

Global Nanomedicine Market: Restraints

Lack of organized regulatory framework is expected to hinder growth of the global nanomedicine market. There are presently no specific testing requirements for nanomedicine. However, the safety testing requirements of the FDA, CDER and other regulatory authorities worldwide for any medical products is very stringent. Nanomedicine products are associated with environmental and toxicological issues, which make it mandatory for manufacturers to perform toxic studies and abide with environmental regulations while manufacturing. Current preclinical tests for safety evaluation include tests such as toxicology, pharmacology, ADME, carcinogenicity, immunotoxicity and genotoxicity.

Moreover, low adoption of nanomedicine in emerging economies is also expected to limit the market growth. 

request-sample

Nanomedicine Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 177.1 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 12.5% 2027 Value Projection: US$ 454.8 Bn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Application: Cardiovascular, Anti-inflammatories, Anti-infective, Neurology, Oncology, Others (dental, orthopedic, urology, opthalmic).
Companies covered:

Abbott Laboratories, CombiMatrix Corporation, Clene Nanomedicine, Inc., Cellics Therapeutics, Inc., Nanobiotix S.A, Celgene Corporation, GE Healthcare, NanoViricides, Inc., Johnson & Johnson, Mallinckrodt plc., Sirnaomics Inc., Precision NanoSystems Inc., Merck & Company Inc., Nanosphere, Inc., Pfizer Inc., and Sigma-Tau Pharmaceuticals Inc.

Growth Drivers:
  • Increasing prevalence of chronic diseases
  • Approval and launch of new products
Restraints & Challenges:
  • Lack of organized regulatory framework

Global Nanomedicine Market: Opportunities  

Presence of unmet medical needs in emerging economies is expected to offer lucrative growth opportunities for players in the global nanomedicine market. Emerging and high growth markets such as China, Brazil, India, Eastern Europe, Middle East, and Latin America are expected to offer a vast arena of opportunities for the nanomedicine market in future. This is due to the fact that economic development in these economies has equipped patients with purchasing power induced by rising disposable incomes. Improvement of healthcare infrastructure will enable use of sophisticated technologies and cater to the high unmet medical needs of the population.

Moreover, R&D in nanomedicine is also expected to aid in growth of the market. For instance, in August 2020, researchers at the Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, Germany, reported that superparamagnetic iron oxide nanoparticles can function as an effective delivery platform to increase local drug concentrations, thereby potentially overcoming chemotherapy resistance of cells.

Statistics:

The global nanomedicine market was valued at US$ 177.1 Bn in 2019 and is forecast to reach a value of US$ 454.8 Bn by 2027 at a CAGR of 12.5% between 2020 and 2027.

Figure 2: Global Nanomedicine Market Value (US$ Bn), 2016 – 2027

Nanomedicines  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the global nanomedicine market are focused on R&D of new products to expand their product portfolio. For instance, in August 2020, Clene Nanomedicine, Inc. announced that the Sean M Healey & AMG Center for ALS at Mass General enrolled the first patients into the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS (NEALS) consortium. The company’s CNM-Au8, a therapeutic nanocatalyst was selected as one of the first drug regimens to be evaluated as an ALS treatment in the HEALEY ALS Platform Trial.

Investment in nanomedicine is expected to propel growth of the global nanomedicine market. For instance, in July 2020, Curadigm SAS, a wholly-owned subsidiary of Nanobiotix S.A., announced the receipt of US$ 1.18 million in non-dilutive funding from Deep Tech BPI France for the development of their Nanoprimer technology.

Global Nanomedicine Market: Competitive Landscape

Major players operating in the global nanomedicine market include, Abbott Laboratories, CombiMatrix Corporation, Clene Nanomedicine, Inc., Cellics Therapeutics, Inc., Nanobiotix S.A, Celgene Corporation, GE Healthcare, NanoViricides, Inc., Johnson & Johnson, Mallinckrodt plc., Sirnaomics Inc., Precision NanoSystems Inc., Merck & Company Inc., Nanosphere, Inc., Pfizer Inc., and Sigma-Tau Pharmaceuticals Inc.

Global Nanomedicine Market: Key Developments

Major players in the global nanomedicine market are focused on R&D of new products to expand their product portfolio. For instance, in June 2020, Nanobiotix S.A announced that the FDA has provided necessary feedback regarding the design of NANORAY-312, the company’s pivotal phase III global registration trial in head and neck cancer.

Similarly, in June 2020, Cellics Therapeutics, Inc. announced that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters.

Nanomedicine products have applications in drug delivery, in vivo imaging, in vitro diagnostics, regenerative medicine, dental, medical devices, and dermal applications. Major drivers for the global nanomedicine market constitutes of increasing government support as well as continuous increase in the occurrence of chronic diseases including diabetes, obesity, cancer, orthopedic diseases, and kidney disorder. Furthermore, major players in the global nanomedicine market are focused on R&D of new products to expand their product portfolio.

Key features of the study:

  • This report provides in-depth analysis of the Global Nanomedicines market  and provides market size (US$ billion) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global Nanomedicines market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Abbott Laboratories, CombiMatrix Corporation, Clene Nanomedicine, Inc., Cellics Therapeutics, Inc., Nanobiotix S.A, Celgene Corporation, GE Healthcare, NanoViricides, Inc., Johnson & Johnson, Mallinckrodt plc., Sirnaomics Inc., Precision NanoSystems Inc., Merck & Company Inc., Nanosphere, Inc., Pfizer Inc., and Sigma-Tau Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global Nanomedicines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Nanomedicines market

Detailed Segmentation:

  • Global Nanomedicines Market, By Application:
    • Cardiovascular
    • Anti-inflammatories
    • Anti-infectives
    • Neurology
    • Oncology
    • Others (dental, orthopedic, urology, ophthalmic)
  • Global Nanomedicines Market, By Region:
    • North America
      • By Application
        • Cardiovascular
        • Anti-inflammatories
        • Anti-infectives
        • Neurology
        • Oncology
        • Others (dental, orthopedic, urology, ophthalmic)
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Application
        • Cardiovascular
        • Anti-inflammatories
        • Anti-infectives
        • Neurology
        • Oncology
        • Others (dental, orthopedic, urology, ophthalmic)
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Application
        • Cardiovascular
        • Anti-inflammatories
        • Anti-infectives
        • Neurology
        • Oncology
        • Others (dental, orthopedic, urology, ophthalmic)
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Application
        • Cardiovascular
        • Anti-inflammatories
        • Anti-infectives
        • Neurology
        • Oncology
        • Others (dental, orthopedic, urology, ophthalmic)
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Application
        • Cardiovascular
        • Anti-inflammatories
        • Anti-infectives
        • Neurology
        • Oncology
        • Others (dental, orthopedic, urology, ophthalmic)
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Application
        • Cardiovascular
        • Anti-inflammatories
        • Anti-infectives
        • Neurology
        • Oncology
        • Others (dental, orthopedic, urology, ophthalmic)
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Abbott Laboratories *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • CombiMatrix Corporation
    • Clene Nanomedicine, Inc.
    • Cellics Therapeutics Inc.
    • Nanobiotix S.A
    • Celgene Corporation
    • GE Healthcare
    • NanoViricides, Inc.
    • Johnson & Johnson
    • Mallinckrodt plc.
    • Sirnaomics Inc.
    • Precision NanoSystems Inc.
    • Merck & Company Inc.
    • Nanosphere, Inc.
    • Pfizer Inc.
    • Sigma-Tau Pharmaceuticals Inc.
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Application
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
  4. Global Nanomedicines Market, By Application, 2019 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Cardiovascular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Anti-inflammatories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Anti-infective
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Neurology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Others (dental, orthopedic, urology, opthalmic)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  5. Global Nanomedicines Market, By Region, 2019 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • North Africa
        • Central Africa
        • South Africa
  6. Competitive Landscape
    • Company Profiles
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CombiMatrix Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Clene Nanomedicine, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cellics Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nanobiotix S.A
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GE Healthcare
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NanoViricides, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mallinckrodt plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sirnaomics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Precision NanoSystems Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Company Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nanosphere, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sigma-Tau Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 14 figures on “Nanomedicines Market - Global forecast to 2027”.

Frequently Asked Questions

The Global Nanomedicines market size was valued at US$ 177.1 billion in 2019 and is estimated to exhibit a CAGR of 12.5% between 2020 and 2027.
Oncology segment held the major market share in 2019 owing to an increasing prevalence of cancer
Major factor driving the growth of Global Nanomedicines market during the forecast period increasing prevalence of chronic diseases, increasing research & development , and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global Nanomedicines market during the forecast period constitutes of contamination of lack of reimbursement.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Abbott Laboratories, CombiMatrix Corporation, Clene Nanomedicine, Inc., Cellics Therapeutics, Inc., Nanobiotix S.A, Celgene Corporation, GE Healthcare, NanoViricides, Inc., Johnson & Johnson, Mallinckrodt plc. Sirnaomics Inc., Precision NanoSystems Inc., Merck & Company Inc., Nanosphere, Inc., Pfizer Inc., and Sigma-Tau Pharmaceuticals Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner